文献速递心律失常

氟卡尼治疗儿茶酚胺敏感性多形性室性心动过速的随机临床试验

Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2017-01-01

这项由研究者发起的多中心单盲安慰剂对照交叉试验纳入14例植入ICD的CPVT患者,在最大耐受β受体阻滞剂基础上比较氟卡尼与安慰剂。结果显示氟卡尼显著降低运动诱发的室性心律失常评分(中位数0 vs 2.5,P<.01),13例中11例(85%)完全抑制,不良事件无差异。

要点

  • 氟卡尼联合β受体阻滞剂较安慰剂联合β受体阻滞剂显著降低运动室性心律失常评分。
  • 13例完成者中11例(85%)运动时室性心律失常完全抑制。
  • 氟卡尼与安慰剂组总体及严重不良事件无差异。

核心结论

  • 在CPVT患者中,氟卡尼联合β受体阻滞剂较安慰剂联合β受体阻滞剂及单用β受体阻滞剂显著减少运动时室性异位搏动。

研究设计与样本

  • 纳入临床诊断CPVT且植入ICD的患者,在最大耐受β受体阻滞剂治疗基础上随机接受氟卡尼或安慰剂3个月后行运动试验,洗脱1周后交叉至另一治疗3个月再行运动试验。
  • 共随机14例(男7例、女7例;中位年龄16岁,四分位距15.0-22.5岁),13例完成研究。

主要发现

  • 基线运动试验评分中位数3.0(范围0-4),基线与此后安慰剂期评分(中位数2.5,范围0-4)无差异。
  • 运动时室性心律失常评分中位数氟卡尼组0(范围0-2)vs 安慰剂组2.5(范围0-4),氟卡尼组显著降低(P<.01)。
  • 13例中11例(85%)在氟卡尼治疗下运动时室性心律失常完全抑制。
  • 氟卡尼组与安慰剂组总体不良事件及严重不良事件无差异。

关键数值与推荐

  • 运动试验按最差室性心律失常的序数量表评分:0为无期前搏动,1为孤立室性期前搏动,2为二联律,3为成对室早,4为非持续性室性心动过速。
  • 氟卡尼口服每日两次,剂量依据谷浓度血清水平调整。

临床怎么用

  • 对于已植入ICD并在最大耐受β受体阻滞剂治疗下的CPVT患者,加用氟卡尼(按谷浓度调整剂量)可显著减少运动诱发的室性心律失常。
  • 本试验中氟卡尼与安慰剂的不良事件无差异。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a potentially lethal genetic arrhythmia syndrome characterized by polymorphic ventricular tachycardia with physical or emotional stress, for which current therapy with β-blockers is incompletely effective. Flecainide acetate directly suppresses sarcoplasmic reticulum calcium release-the cellular mechanism responsible for triggering ventricular arrhythmias in CPVT-but has never been assessed prospectively. OBJECTIVE: To determine whether flecainide dosed to therapeutic levels and added to β-blocker therapy is superior to β-blocker therapy alone for the prevention of exercise-induced arrhythmias in CPVT. DESIGN, SETTING, AND PARTICIPANTS: This investigator-initiated, multicenter, single-blind, placebo-controlled crossover clinical trial was conducted from December 19, 2011, through December 29, 2015, with a midtrial protocol change at 10 US sites. Patients with a clinical diagnosis of CPVT and an implantable cardioverter-defibrillator underwent a baseline exercise test while receiving maximally tolerated β-blocker therapy that was continued throughout the trial. Patients were then randomized to treatment A (flecainide or placebo) for 3 months, followed by exercise testing. After a 1-week washout period, patients crossed over to treatment B (placebo or flecainide) for 3 months, followed by exercise testing. INTERVENTIONS: Patients received oral flecainide or placebo twice daily, with the dosage guided by trough serum levels. MAIN OUTCOMES AND MEASURES: The primary end point of ventricular arrhythmias during exercise was compared between the flecainide and placebo arms. Exercise tests were scored on an ordinal scale of worst ventricular arrhythmia observed (0 indicates no ectopy; 1, isolated premature ventricular beats; 2, bigeminy; 3, couplets; and 4, nonsustained ventricular tachycardia). RESULTS: Of 14 patients (7 males and 7 females; median age, 16 years [interquartile range, 15.0-22.5 years]) randomized, 13 completed the study. The median baseline exercise test score was 3.0 (range, 0-4), with no difference noted between the baseline and placebo (median, 2.5; range, 0-4) exercise scores. The median ventricular arrhythmia score during exercise was significantly reduced by flecainide (0 [range, 0-2] vs 2.5 [range, 0-4] for placebo; P < .01), with complete suppression observed in 11 of 13 patients (85%). Overall and serious adverse events did not differ between the flecainide and placebo arms. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of patients with CPVT, flecainide plus β-blocker significantly reduced ventricular ectopy during exercise compared with placebo plus β-blocker and β-blocker alone. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01117454.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Kannankeril PJ, Moore JP, Cerrone M, et al. Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial. JAMA Cardiol. 2017. PMID: 28492868. doi:10.1001/jamacardio.2017.1320

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。